These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3413038)

  • 1. Does hyperthermia decrease negative feedback in nigrostriatal dopaminergic neurons?
    Lee TH; Ellinwood EH; Nishita JK; Hoffman GW
    Pharmacol Toxicol; 1988 May; 62(5):344-5. PubMed ID: 3413038
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there a non-dopaminergic nigrostriatal pathway?
    van der Kooy D; Coscina DV; Hattori T
    Neuroscience; 1981; 6(3):345-57. PubMed ID: 7012667
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute and chronic treatment with neuroleptics: similarities and differences in their action on nigrostriatal, mesolimbic, and mesocortical dopaminergic neurons.
    Julou L; Scatton B; Glowinski J
    Adv Biochem Psychopharmacol; 1977; 16():617-24. PubMed ID: 18904
    [No Abstract]   [Full Text] [Related]  

  • 5. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anesthetic influences on the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons.
    Kelland MD; Chiodo LA; Freeman AS
    Synapse; 1990; 6(2):207-9. PubMed ID: 1978421
    [No Abstract]   [Full Text] [Related]  

  • 7. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
    Lindner MD; Cain CK; Plone MA; Frydel BR; Blaney TJ; Emerich DF; Hoane MR
    Behav Brain Res; 1999 Jul; 102(1-2):1-16. PubMed ID: 10403011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Fine A; Hunt SP; Oertel WH; Nomoto M; Chong PN; Bond A; Waters C; Temlett JA; Annett L; Dunnett S
    Prog Brain Res; 1988; 78():479-89. PubMed ID: 3150110
    [No Abstract]   [Full Text] [Related]  

  • 9. Single dopaminergic nigrostriatal neurons form two chemically distinct synaptic types: possible transmitter segregation within neurons.
    Hattori T; Takada M; Moriizumi T; Van der Kooy D
    J Comp Neurol; 1991 Jul; 309(3):391-401. PubMed ID: 1717519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological analysis of the functional ontogeny of the nigrostriatal dopaminergic neurons.
    Cheronis JC; Erinoff L; Heller A; Hoffmann PC
    Brain Res; 1979 Jun; 169(3):545-60. PubMed ID: 36209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic haloperidol treatment: effects on nigrostriatal dopaminergic system activity.
    Bunney BS; Skirboll LR; Grace AA
    Adv Biochem Psychopharmacol; 1980; 24():267-73. PubMed ID: 7405666
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between the presence of dopaminergic neurons and GABA receptors in substantia nigra: effects of lesions.
    Gale K
    Brain Res; 1981 Apr; 210(1-2):401-6. PubMed ID: 6112044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-Amphetamine-induced inhibition of central dopaminergic neurons: direct effect or mediated by a striatonigral feedback pathway?
    Bunney BS; Aghajanian GK
    Adv Biochem Psychopharmacol; 1977; 16():577-82. PubMed ID: 883560
    [No Abstract]   [Full Text] [Related]  

  • 15. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of striatal methionin enkephalin content following lesion of the nigrostriatal dopaminergic pathway in adult rats and reversal following the implantation of embryonic dopaminergic neurons: a quantitative immunohistochemical analysis.
    Manier M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
    Neuroscience; 1991; 42(2):427-39. PubMed ID: 1896133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gamma-Aminobutyric acid function in the rat striatum is under the double influence of nigrostriatal dopaminergic and thalamostriatal inputs: two modes of regulation?
    Samuel D; Kumar U; Nieoullon A
    J Neurochem; 1988 Dec; 51(6):1704-10. PubMed ID: 3141584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal, pallidal, and pars reticulata evoked inhibition of nigrostriatal dopaminergic neurons is mediated by GABA(A) receptors in vivo.
    Paladini CA; Celada P; Tepper JM
    Neuroscience; 1999 Mar; 89(3):799-812. PubMed ID: 10199614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E; Hefti F
    Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-dopaminergic nigrostriatal pathway.
    Guyenet PG; Crane JK
    Brain Res; 1981 Jun; 213(2):291-305. PubMed ID: 7248760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.